A Review on Gastro-Intestinal Drug Esomeprazole
Abstract
Esomeprazole is a proton pump inhibitor used to treat gastric problems mainly peptic ulcers. Peptic ulcers are present in around 4% of the population. They newly began in around 53 million people in 2013. About 10% of people develop a peptic ulcer at some point in their life. They resulted in 301,000 deaths in 2013 down from 327,000 deaths in 1990. The first description of a perforated peptic ulcer was in 1670 in Princess Henrietta of England .H. pylori was first identified as causing peptic ulcers by Barry Marshall and Robin Warren in the late 20th century, a discovery for which they received the Nobel Prize in 2005. Esomeprazole comes under non-surgical treatment for peptic ulcers. Though it is an effective drug used for the treatment of peptic ulcers it includes some side effects such as headache, nausea, diarrhea, decreased appetite etc., optical isomer of omeprazole is called as s-isomer of omeprazole or esomeprazole which is an improved form of omeprazole. Esomeprazole in combination with cardiovascular drugs produces potential interactions and positive effects.This review article provides an evaluation of the literature on the concomitant use of esomeprazole available. The efficacy, safety, tolerability, cost effectiveness, and patient quality of life of this regimen is discussed. A summary of the pharmacokinetic and pharmacodynamic interactions of esomeprazole, Mechanism of action of omeprazole, as well as its effects during pregnancy are also reviewed.
References
2. Kahrilas, PJ. Gastroesophageal reflux disease. New England Journal of Medicine; 2008; 359(16): 1700-1707.
3. Clark, DW; Strandell J; Myopathy including polymyositis: a likely class adverse effect of proton pump inhibitors?; European Journal of Clinical Pharmacology; 2006; 62(6); 473–479
4. Health line-Stomach ulcer written by Shannon Johnson Medically Reviewed by Steven Kim, MD on August 25, 2015
5. R. Baselt, Disposition of Toxic Drugs and Chemicals in Man, 8th edition, Biomedical Publications, Foster City, CA, 2008, pp. 388-389.
6. A PROTON-PUMP INHIBITOR EXPEDITION: THE CASE HISTORIES OF OMEPRAZOLE AND ESOMEPRAZOLE - Lars Olbe, Enar Carlsson and Per Lindberg-AstraZeneca R&D,431 83 Mölndal, Sweden.
7. Stedman CA, Barclay ML; Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors; Aliment. Pharmacol. Ther. ; 2000; 14(8); 963–78.
8. Herzig SJ, Howell MD, Ngo LH, Marcantonio ER ."Acid-suppressive medication use and the risk for hospital-acquired pneumonia". JAMA. 2009; 301 (20); 2120–2128
9. Esomeprazole Magnesium; The American Society of Health-System Pharmacists. Retrieved 3 April 2011.
10. Li J, Zhao J, Hamer-Maansson JE, Andersson T, Fulmer R, Illueca M, Lundborg P; Pharmacokinetic properties of esomeprazole in adolescent patients aged 12 to 17 years with symptoms of gastroesophageal reflux disease: A randomized, open-label study; Clin Ther.; 2006; 28(3); 419–27.
11.Umaee FarmMed , Posted by Umaee Azanuddin at 8:37 PM, Algorithm For Treatment of Peptic Ulcer Disease , Source: Pharmacotherapy 7th
